Viking's VK2735 mimics both GLP-1 and GIP hormones, aiming for superior weight loss compared to established medications like Novo Nordisk A/S's (NYSE:NVO) Wegovy and Eli Lilly And Co's (NYSE:LLY) ...
Topping Viking's portfolio with a 5.6% allocation, U.S. Bancorp represents a significant long-term bet. Viking increased its position by 32.33% in Q3, bringing its total to 33.6 million shares worth ...
The closely-watched biotech is doing well with an investigational weight-loss treatment. It also revealed in its third-quarter earnings release that its holdings of liquid securities had swelled to ...
SAN DIEGO, July 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine ...
River cruise operator Viking reported first-quarter results on Wednesday morning. The stock sank on the news. Viking's revenue rose 14% -- less than traditional cruise line companies -- but there are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results